Understanding the impact of immune-related side effects in arthritis patients after immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the severity and nature of experiences related to rheumatic immune-related adverse events (irAEs) in patients who have undergone immune checkpoint inhibitor immunotherapy. It will explore the functional impact of these adverse events on participants' lives and gather insights into their attitudes towards these experiences. By conducting qualitative assessments, the study seeks to provide a deeper understanding of the challenges faced by patients with inflammatory arthritis or polymyalgia rheumatica following treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria

The criteria are:

* Patients aged 18 years and above
* English (conversational level) speaking, with the ability to give informed consent
* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy

Exclusion Criteria

* Acutely life-threatening or worsening cancer
* Hearing impairment functionally limiting participation in verbal interview

Where it's running

• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Y. Jeff Li, MD — M.D. Anderson Cancer Center
• Study coordinator: Y. Jeff Li, MD
• Email: yli61@mdanderson.org
• Phone: 713-409-1565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• Adjuvant sintilimab after neoadjuvant therapy and surgery for high-risk NSCLC

  This trial tests whether giving sintilimab after surgery helps prevent cancer from returning in people with high-risk non-small cell lung cancer who already had neoadjuvant immunochemotherapy and surgery.

  Recruiting at 2 sites Phase 2 Sichuan University · Chengdu, Sichuan and 1 other locations · NCT07748325

• Predictive biomarkers for immunotherapy in endometrial cancer

  This study tests molecular and epigenetic features to see if they can predict which endometrial cancer patients will respond to immune checkpoint inhibitors.

  Recruiting European Institute of Oncology · Milan, Italy · NCT07690540

• Observational cohort of chronic brain viral infections (including PML)

  This project will try immune checkpoint inhibitors in people with chronic central nervous system viral infections like PML to see if they lead to better long-term outcomes.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07512518

• Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response

  This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07372079

• Ultrasound Before Corticosteroid Injection for Arthritis

  This trial tests whether applying ultrasound before a corticosteroid joint injection helps improve arthritis symptoms in adults with limb arthritis who need an injection.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07363876

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.